Facilities

Phase 1 Capability

Phase 1 population

Solid tumours and haematological malignancy in adults and children

Mechanisms studied

  • Genetic variation in leukaemia
  • Gene expression, microarrays
  • Immunohistochemistry, tissue microarrays
  • Posphor-imaging for target and therapeutic location on tumours and normal tissue biopsies
  • Pharmacogenomics
  • Pharmacokinetics by HPLC for various drugs
  • DNA strand breaks, cross-linking and repair
  • Tumour localisation of therapeutics by SPECT with dosimetry
  • FDG-PET for tumour response
  • DCE-MRI for tumour blood flow and perfusion
  • BOLD-MRI
  • CT perfusion
  • Electron Scattering Spectroscopy
  • Cellular and humoral immune responses

First-in-Man studies

Yes

Centre specific translational research interest

Broad range of interests in small molecules, protein, physical and cellular therapies and mechanisms related to them.

Multi-centre Phase 1 studies

Yes, and we currently do so

 

Technology/equipment available within the centre

  • Affymetrix GeneChip Microarray System
  • Hamilton Microlab STAR with SWAP arm
  • Kratos Analytical AXIMA CFR Mass Spectrometer
  • Leica TCS SP Confocal Microscope
  • Electron Microscopy
  • Leitz Digital Fluorescence Microscopy
  • Advanced ChemTech 396 Peptide Synthesiser
  • Beckmann Coulter CEQ 8000 DNA Sequencers
  • Becton Dickinson FACSCalibur
  • Cytomation Mo-Flo Cell Sorte
  • AKTA FPLC Systems
  • Shimadzu and Gilson analytical and Gilson preparative HPLCs
  • qPCR ABI Prism 7700
  • PDT and Laser therapy
  • Elastic scattering spectroscopy
  • SPECT Imaging
  • 64 slice PET/CT
  • 16 slice PET/CT
  • FDG Programme
  • CT Perfusion
  • 82Rb Perfusion
  • Radionuclide Therapy Programme
  • Large Radio pharmacy
  • BOLD MRI
  • Proteomics by Mass Spectroscopy
  • Proteomics by 2D gel electrophoreses
  • Gene Expression Array
  • Tissue Microarray
  • GMP approved recombinant protein production facility
  • IMP-licensed radio-labelling facility
 

Other Facilities (e.g. Wellcome Trust CRF)

Wellcome Trust CRF due to open in April 2008 with specialised cancer trials area, imaging GCLP laboratories and trials pharmacy

 

Sample collection

Tissue Banking Activity

Adenocarcinoma, neuroendocrine tissue

Centre contact responsible for sample collection

Contact Helen MacColl for this information (email: h.maccoll@medsch.ucl.ac.uk)

 

Hospital sites

  • The Royal Free
  • UCL Hospital